Post Reply
7761-7780 of 10899
here some level to look at.... 0.88 ........ 0.915 ........0.945 ........0.99 .......1.03............ let see how it close....
.895
| 16:21:37 | 0.875 | 10,000 | Sell Down |
| 16:21:28 | 0.880 | 20,000 | Buy Up |
| 16:21:20 | 0.875 | 5,000 | Sell Down |
| 16:21:18 | 0.875 | 10,000 | Sell Down |
| 16:21:11 | 0.875 | 20,000 | Sell Down |
| 16:21:09 | 0.875 | 1,164,000 | Buy Up |
| 16:21:08 | 0.870 | 10,000 | Sell Down |
| 16:21:08 | 0.875 | 10,000 | Buy Up |
| 16:21:03 | 0.875 | 20,000 | Buy Up |
| 16:20:58 | 0.870 | 9,000 | Buy Up |
| 16:20:57 | 0.870 | 598,000 | Buy Up |
No fear XiaoMaGe88!You SEE!!!!!!!!!!!!!!!!!!!!!!!!!
CHEONG!!!!!!!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!
let close above 90C
cheong....har.......
No fear XiaoMaGe88!
If you are holding for $3.00 per share, you just have to wait. I don't look at this counter share price too frequently now because I know the day for TO is drawing nearer and nearer by the days. But I now learn from one of you not to look at the TO, but at the potential of the company in the years ahead. Holding on fast!
BIG!!!!!!!!!!!!!!!!!!!!!
| Impossible Member |
Posted: 25-Feb-2008 10:55 |
 x 0  x 0 |
Bengster, do you know when will BIG's patent "any limus drug on biodegredable polymer" expire? Thanks. |
uncle seng really dragging BIG down along with it, back to opening price...
Bengster, do you know when will BIG's patent "any limus drug on biodegredable polymer" expire? Thanks.
Come on BBs, you know better whats going on and the time could be near. At this price, BIG still can make very good money for you. There are a few other BBs buying too. Don't wait too long until something like 12/02/2008 (Tues morning) happen. From 76cts wait and don't buy shoot up until 85cts. Better not wait anymore. Buying action may start when you least expect it. The market / charts shows this stock is on firm uptrend now and forget about trying to collect it cheap. 87cts is cheap already. What is 1 cts difference in your buying price compared to the BIG fat profit you are going to make???
THE TRAIN IS LEAVING WITH OR WITHOUT YOU!!!
THE TRAIN IS LEAVING WITH OR WITHOUT YOU!!!
BIG!!!!!!!!!!!!!!!!!!!!READY 
!!!!!!!!!!!!!!!!!TO 
!!!!!!!!!!!!!!!!!TO
| 09:02:28 | 0.870 | 25,000 | Buy Up |
| 09:02:19 | 0.865 | 10,000 | Buy Up |
| 09:02:07 | 0.870 | 523,000 | Buy Up |
May i borrow a sentence from Warren Buffet that may offend many investors that are practising equity diversification portfolio management: "Diversification is for birds. Buy only a few good companies that you know best and watch them very carefully."
When kena selldown, blue chips will not be spared. S-shares with very low PE will not be spared as well. Needless to say, pennies will be the worst hit. BIG is volatile but not a risky stock to me. Let me share with you an old news to further show you BIG's real potential:
Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions Article Date: 08 May 2007
Citing issues related to potentially sub-optimal therapeutic dosing of paclitaxel, Conor Medsystems, LLC has concluded that the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial, the pivotal study for the CoStar(R) cobalt chromium paclitaxel-eluting coronary stent, failed to meet its primary endpoint. The trial did not identify safety issues, and the overall rates of death, myocardial infarction and stent thrombosis were consistent with those observed in other clinically relevant drug-eluting stent studies.
As a result of these outcomes, the company will terminate ongoing clinical trials with the CoStar(R) stent and will not conclude the submission of its Pre-Market Approval application to the U.S. Food and Drug Administration for the product. Further, Conor Medsystems will discontinue sale of the product through commercial partners in certain countries in Europe, Asia and Latin America where the CoStar stent is already approved, and will work with those partners to facilitate return of product in inventory in customer accounts.
The COSTAR II trial compared the CoStar(R) stent with the Taxus Express(2) paclitaxel drug-eluting stent, and was designed to demonstrate non-inferiority at eight-month follow-up with respect to major adverse cardiac events (MACE) in patients with multi-vessel or single-vessel disease. In this trial, MACE was defined as a composite of clinically driven target vessel revascularization, heart attack (new myocardial infarction) related to the target vessel and cardiac death related to an intervened vessel.
"While we are disappointed in these results, we remain optimistic about the ability of the novel Conor Medsystems reservoir platform to provide precise and controlled delivery of a therapeutic agent based on earlier proof of concept testing and trials," said Campbell Rogers, M.D., chief technology officer, cardiovascular franchise. "Unfortunately, the dose of paclitaxel used in this trial was ineffective. We expect that the continued development of sirolimus on this platform will demonstrate promising outcomes, because sirolimus has been shown to be a versatile and potent anti-restenosis agent with a wide therapeutic dosing range."
Sirolimus is the proven drug used with the CYPHER(R) Sirolimus-eluting Coronary Stent -- the most widely studied coronary stent in the world.
"While the safety data from this trial are consistent with other drug-eluting stent studies, it was disappointing that this product did not meet the high standards for efficacy that our product portfolio represents," said Rick Anderson, Johnson & Johnson Company Group Chairman and worldwide cardiovascular franchise leader. "At the same time, as we have indicated since the acquisition of Conor Medsystems, we are enthusiastic about the development of this platform with a versatile, highly effective drug like sirolimus. Going forward, our clinical program will be heavily focused on the study of sirolimus on the platform, as well as on investigating the vast library of therapeutic agents accessible to our scientists through the research and development programs of pharmaceutical companies in the Johnson & Johnson family of companies."
*** JNJ is experimenting Costar's biodegredable polymer and metal strut with reservoir holes platform using Sirolimus drug. Effectively, this new product will be in breach of BIG's "any limus drug on biodegredable polymer". Many industry experts have said this new DES will not work because the problem is due to metal struts with reservoir holes. Even if this product really works eventually, it will in breach of BIG's patent. IF BIG is bought over by ABT or MDT, do you think they will allow JNJ patent breach waiver? So what if JNJ can offer US$300m lump sum payment plus 20% royalty from sales? The industry big boys will never allow their key patent to be breached and will never allow main rivals to infringe their key patent even with very lucrative offers. They will be shooting their own foot! Same fate for ABT with their ABSORB DES program. This is how powerful BIG's patent really is. This patent has very wide fencing and many "new DES development/programs" will be caught. The wider the fencing, the better and more valuable the patent will be. Whoever holding this key patent will be the future DES industry leader. Im expect a bidding war for this company eventually. With this patent, you can stop your arch-rivals from developing/commercialising next generation DESs to maintain your market dominance. Get the picture clearer now???
Know more about BIG's real potential and you will start to appreciate this company even more.
Ha Ha... if this stock sink you'll be broke.!
Something is brewing behind the scene.... just be patient.
bengster...being one stock...isn't it much more risky? diversification would be a better choice with stocks...at least spread out the risks...u still have other stocks to cushion upon on should anything unpredictable happen to that one stock...
just my personal point of view in terms of diversification to lower risks..nth against holding biosensors as one single counter in ur portfolio
Im a one stock man now. The rest all liquidated months ago liao. Holding one stock and watching it carefully. I think this stock will give me the best return in 2008.
HAHA! bengster68, pai seh and thanks for the correction. that's what i get for being too lazy to type in full.
Yes, have much faith in BIG (not BSX!). If you can hold, anything below $1 seems like a good deal to me. I believe cashiertan is referring to contra or short-term traders when he says newbies & pros. Too bad not a CPF stock, so my CPF is vested in Informatics (also long term).
Mr. Bengster, besides biosensor, what others you are in?
The gap down after CE announcement on 22/01/08 from 90cts closing to 84.5cts next day opening has been filled. From 18-20/02/2008, 3 days of trading filling the gap from 84.5cts to 89cts. I consider this gap as being "closed" already. Furthermore, the nice finish of 85cts closing on friday is above all 20, 50, 100, 200 MA and looks like its on uptrend.
Just my opinion. Not an inducement to buy. Buy at your own risk.
We need a little bit of faith sometimes but I depend a lot on my own little research and homework. I am convinced this stock will be a multi-bagger investment. All the previous mess has been sorted out except USA market. We should see real significant improvement of this company in 2008.